Protocolo diagnóstico y tratamiento de la hipertensión en el síndrome metabólico y en la diabetes mellitus tipo 2

  1. de la Fuente, G. de Arriba
  2. Tocora, D.G. Gaitán
  3. Sevillano, B. Hernández
  4. del Valle, K.M. Pérez
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2019

Título do exemplar: Enfermedades nefrourinarias (III) Hipertensión y enfermedades vasculares renales

Serie: 12

Número: 81

Páxinas: 4800-4803

Tipo: Artigo

DOI: 10.1016/J.MED.2019.06.008 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Clinically, hypertensive patient has to be assessed according with a global perspective including all cardiovascular risk factors, not only artery blood pressure. The term metabolic syndrome encompasses all these factors, also including obesity, plasma lipid levels and glycemia. Treatment follows a multiple approach. On the other hand, type 2 diabetes mellitus patients frequently suffer artery hypertension requiring a specific therapeutic approach.

Referencias bibliográficas

  • Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5.
  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603-15.
  • Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007;49(4):403-14.
  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21(1):1-6.
  • Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6): 393-403.
  • Owen JG, Reisin E. Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications. Curr Hyper-tens Rep. 2015;17(6):558.
  • Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C. 2017 Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324.
  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.
Fonte de datos: Dialnet